Resolving the micro-heterogeneity and structural integrity of monoclonal antibodies by hybrid mass spectrometric approaches

Yang Yang, Guanbo Wang, Ting Song, Carlito B Lebrilla, Albert J R Heck

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

For therapeutic monoclonal antibodies (mAbs), detailed analysis of the structural integrity and heterogeneity, which results from multiple types of post-translational modifications (PTMs), is relevant to various processes, including product characterization, storage stability and quality control. Despite the recent rapid development of new bioanalytical techniques, it is still challenging to completely characterize the proteoform profile of a mAb. As a nearly indispensable tool in mAb analysis, mass spectrometry (MS) provides unique structural information at multiple levels. Here, we tested a hybrid strategy for the comprehensive characterization of micro-heterogeneity by integrating 2 state-of-the-art MS-based approaches, high-resolution native MS and targeted glycan profiling, to perform complementary analysis at the intact protein level and released glycan level, respectively. We compared the performance of these methods using samples of engineered half-body IgG4s and a panel of mAbs approved for human use. The glycosylation characterization data derived from these approaches were found to be mutually consistent in composition profiling, and complementary in identification and relative-quantitation of low-abundant uncommon glycoforms. In addition, multiple other sources of micro-heterogeneity, such as glycation, lack of glycosylation, and loss of light chains, could be detected by this approach, and the contribution of multiple types of modifications to the overall micro-heterogeneity could be assessed using our superposition algorithm. Our data demonstrate that the hybrid strategy allows reliable and thorough characterization of mAbs, revealing product characteristics that would easily be missed if only a single approach were used.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalmAbs
DOIs
StateAccepted/In press - Mar 9 2017

Fingerprint

Mass Spectrometry
Monoclonal Antibodies
Glycosylation
Polysaccharides
Post Translational Protein Processing
Quality Control
Light
Proteins
Therapeutics

Keywords

  • Bevacizumab
  • Eculizumab
  • glycosylation
  • IgG
  • Infliximab
  • mAb structural integrity
  • native mass spectrometry
  • Ofatumumab
  • Panitumumab
  • Rituximab
  • Trastuzumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Resolving the micro-heterogeneity and structural integrity of monoclonal antibodies by hybrid mass spectrometric approaches. / Yang, Yang; Wang, Guanbo; Song, Ting; Lebrilla, Carlito B; Heck, Albert J R.

In: mAbs, 09.03.2017, p. 1-8.

Research output: Contribution to journalArticle

Yang, Yang ; Wang, Guanbo ; Song, Ting ; Lebrilla, Carlito B ; Heck, Albert J R. / Resolving the micro-heterogeneity and structural integrity of monoclonal antibodies by hybrid mass spectrometric approaches. In: mAbs. 2017 ; pp. 1-8.
@article{2051350538c04ef0bf2640e5e1f8bf9a,
title = "Resolving the micro-heterogeneity and structural integrity of monoclonal antibodies by hybrid mass spectrometric approaches",
abstract = "For therapeutic monoclonal antibodies (mAbs), detailed analysis of the structural integrity and heterogeneity, which results from multiple types of post-translational modifications (PTMs), is relevant to various processes, including product characterization, storage stability and quality control. Despite the recent rapid development of new bioanalytical techniques, it is still challenging to completely characterize the proteoform profile of a mAb. As a nearly indispensable tool in mAb analysis, mass spectrometry (MS) provides unique structural information at multiple levels. Here, we tested a hybrid strategy for the comprehensive characterization of micro-heterogeneity by integrating 2 state-of-the-art MS-based approaches, high-resolution native MS and targeted glycan profiling, to perform complementary analysis at the intact protein level and released glycan level, respectively. We compared the performance of these methods using samples of engineered half-body IgG4s and a panel of mAbs approved for human use. The glycosylation characterization data derived from these approaches were found to be mutually consistent in composition profiling, and complementary in identification and relative-quantitation of low-abundant uncommon glycoforms. In addition, multiple other sources of micro-heterogeneity, such as glycation, lack of glycosylation, and loss of light chains, could be detected by this approach, and the contribution of multiple types of modifications to the overall micro-heterogeneity could be assessed using our superposition algorithm. Our data demonstrate that the hybrid strategy allows reliable and thorough characterization of mAbs, revealing product characteristics that would easily be missed if only a single approach were used.",
keywords = "Bevacizumab, Eculizumab, glycosylation, IgG, Infliximab, mAb structural integrity, native mass spectrometry, Ofatumumab, Panitumumab, Rituximab, Trastuzumab",
author = "Yang Yang and Guanbo Wang and Ting Song and Lebrilla, {Carlito B} and Heck, {Albert J R}",
year = "2017",
month = "3",
day = "9",
doi = "10.1080/19420862.2017.1290033",
language = "English (US)",
pages = "1--8",
journal = "mAbs",
issn = "1942-0862",
publisher = "Landes Bioscience",

}

TY - JOUR

T1 - Resolving the micro-heterogeneity and structural integrity of monoclonal antibodies by hybrid mass spectrometric approaches

AU - Yang, Yang

AU - Wang, Guanbo

AU - Song, Ting

AU - Lebrilla, Carlito B

AU - Heck, Albert J R

PY - 2017/3/9

Y1 - 2017/3/9

N2 - For therapeutic monoclonal antibodies (mAbs), detailed analysis of the structural integrity and heterogeneity, which results from multiple types of post-translational modifications (PTMs), is relevant to various processes, including product characterization, storage stability and quality control. Despite the recent rapid development of new bioanalytical techniques, it is still challenging to completely characterize the proteoform profile of a mAb. As a nearly indispensable tool in mAb analysis, mass spectrometry (MS) provides unique structural information at multiple levels. Here, we tested a hybrid strategy for the comprehensive characterization of micro-heterogeneity by integrating 2 state-of-the-art MS-based approaches, high-resolution native MS and targeted glycan profiling, to perform complementary analysis at the intact protein level and released glycan level, respectively. We compared the performance of these methods using samples of engineered half-body IgG4s and a panel of mAbs approved for human use. The glycosylation characterization data derived from these approaches were found to be mutually consistent in composition profiling, and complementary in identification and relative-quantitation of low-abundant uncommon glycoforms. In addition, multiple other sources of micro-heterogeneity, such as glycation, lack of glycosylation, and loss of light chains, could be detected by this approach, and the contribution of multiple types of modifications to the overall micro-heterogeneity could be assessed using our superposition algorithm. Our data demonstrate that the hybrid strategy allows reliable and thorough characterization of mAbs, revealing product characteristics that would easily be missed if only a single approach were used.

AB - For therapeutic monoclonal antibodies (mAbs), detailed analysis of the structural integrity and heterogeneity, which results from multiple types of post-translational modifications (PTMs), is relevant to various processes, including product characterization, storage stability and quality control. Despite the recent rapid development of new bioanalytical techniques, it is still challenging to completely characterize the proteoform profile of a mAb. As a nearly indispensable tool in mAb analysis, mass spectrometry (MS) provides unique structural information at multiple levels. Here, we tested a hybrid strategy for the comprehensive characterization of micro-heterogeneity by integrating 2 state-of-the-art MS-based approaches, high-resolution native MS and targeted glycan profiling, to perform complementary analysis at the intact protein level and released glycan level, respectively. We compared the performance of these methods using samples of engineered half-body IgG4s and a panel of mAbs approved for human use. The glycosylation characterization data derived from these approaches were found to be mutually consistent in composition profiling, and complementary in identification and relative-quantitation of low-abundant uncommon glycoforms. In addition, multiple other sources of micro-heterogeneity, such as glycation, lack of glycosylation, and loss of light chains, could be detected by this approach, and the contribution of multiple types of modifications to the overall micro-heterogeneity could be assessed using our superposition algorithm. Our data demonstrate that the hybrid strategy allows reliable and thorough characterization of mAbs, revealing product characteristics that would easily be missed if only a single approach were used.

KW - Bevacizumab

KW - Eculizumab

KW - glycosylation

KW - IgG

KW - Infliximab

KW - mAb structural integrity

KW - native mass spectrometry

KW - Ofatumumab

KW - Panitumumab

KW - Rituximab

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85014778973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014778973&partnerID=8YFLogxK

U2 - 10.1080/19420862.2017.1290033

DO - 10.1080/19420862.2017.1290033

M3 - Article

SP - 1

EP - 8

JO - mAbs

JF - mAbs

SN - 1942-0862

ER -